Users Online: 1622
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2017| October-December  | Volume 6 | Issue 4  
    Online since December 21, 2017

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
ORIGINAL ARTICLE: HEAD AND NECK CANCER
Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck
Govind Babu, Ankur Bahl, GS Bhattacharya, KT Bhowmik, PS Dattatraya, Nikhil Ghadyalpatil, SM Karandikar, Padmaj Kulkarni, Nithya Sridharan, Purvish Parikh, Kumar Prabhash, T Raja, S Rajasundaram, S Subramanian, Kaustav Talapatra, Ashok Vaid
October-December 2017, 6(4):154-160
DOI:10.4103/sajc.sajc_181_17  PMID:29404293
We present the 2017 Oncology Gold Standard Practical Consensus Recommendation for use of monoclonal antibodies in the management of advanced squamous cell carcinoma of head neck region.
  1,801 180 -
ORIGINAL ARTICLE: BREAST CANCERS
Male breast cancer: A retrospective review of clinical profile from a tertiary cancer care center of India
Dharma Ram, Suhas K Rajappa, Veda P Selvakumar, Himanshu Shukla, Ashish Goel, Rajeev Kumar, Kapil Kumar
October-December 2017, 6(4):141-143
DOI:10.4103/sajc.sajc_2_17  PMID:29404286
Aim: Present study was done with an aim to analyse the clinicopathological and survival characteristics of male breast cancer patients. Methods: We did a retrospective review of our database and analysed total 27 patients who presented to breast oncology unit of Rajiv Gandhi cancer centre and research institute from January 2010 to April 2016. Results: Most common stage at presentation in our study was in stage II. The median follow up was 32.75 months. The actuarial 5-year survival was 92.30% and DFS was 76.30%. Only hormone receptor status was found as a significant prognostic variable among the prognostic factors studied for disease free survival. Conclusions: Carcinoma breast in male is a relatively rare disease and management principles are translated from our understanding of breast cancer in women. A relatively early stage at presentation is a contrasting finding of our series which may be responsible for a significantly better actuarial 5 year survival rates.
  1,402 257 1
ORIGINAL ARTICLES: PEDIATRIC AND ADOLESCENT CANCERS
Long-term follow-up of retinoblastoma survivors: Experience from India
Rachna Seth, Amitabh Singh, Vijay Guru, Bhavna Chawla, Sushmita Pathy, Savita Sapra
October-December 2017, 6(4):176-179
DOI:10.4103/sajc.sajc_179_16  PMID:29404299
Background: Retinoblastoma (Rb) is the most common primary intraocular tumor of infancy and childhood. Survivors' ocular and visual problems and increased risk for subsequent malignancy are well documented, but data on long-term health status of Rb survivors are limited, this being particularly true for India. Methodology: Children who had completed treatment for Rb at least 2 years ago before and were under follow-up at the after cancer treatment clinic were evaluated. Results: In our series of 213 patients, the median age was 29 months, there was a male preponderance, and majority had unilateral disease. Enucleation was done in almost three-fourth and 3% underwent bilateral enucleation. Majority of the patients received chemotherapy, and few received radiation. Growth was affected in about one-third and majority were those who had received radiation. Diminished vision was noticed in about one-sixth. Orbital hypoplasia and contracted socket were seen in 14.1% cases. 2.7% were hearing impaired. About one-sixth had a global intelligence delay. Second neoplasms were seen in 0.01%. No other abnormalities were seen. Conclusions: Common late effects in our Rb survivors include diminished vision in the salvage eye, intellectual disability, and contracted socket; there is a need for timely institution of prosthesis to avoid late effects such as hypoplasia, contracted sockets, and better cosmesis and enhanced self-esteem. Second neoplasm is a concern. Lifelong follow-up and counseling of a healthy lifestyle are needed for Rb survivors.
  1,330 177 2
ORIGINAL ARTICLE: BONE & SOFT TISSUE TUMORS
Role of percutaneous computed tomography-guided radiofrequency ablation in treatment of osteoid osteoma
Ajay R Upadhyay, Nikunj Chandrakant Desai, Digish U Vaghela
October-December 2017, 6(4):139-140
DOI:10.4103/sajc.sajc_58_17  PMID:29404285
Aim: The aim of the study was to evaluate efficacy of percutaneous computed tomography (CT)-guided radiofrequency ablation (RFA) of nidus in osteoid osteoma (OO). Materials and Methods: RFA was performed on fifty patients with clinically and radiologically diagnosed OO. RFA was done in the department of radio-diagnosis in our institute (a tertiary care providing institute in Ahmedabad, Western India). Ablation was performed by putting at an electrode tip (3–5 mm) into nidus under CT guidance with targeted temperature of 90°C for 3 min. Results: All procedures were technically successful. No immediate major or minor complications were observed. Complete clinical success was achieved in 46 patients. Only four patients required second intervention. Conclusion: Our experience indicates a 98% success rate. No major complications were noted.
  1,201 187 -
ORIGINAL ARTICLES: GASTRO-INTESTINAL & HEPATOBILIARY CANCERS
Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India
Arvind Sahu, Anant Ramaswamy, Nitin Singhal, Vipul Doshi, Jimmy Mirani, Ashwin Desouza, Shripad Banavali, Avanish Saklani, Vikas Ostwal
October-December 2017, 6(4):147-150
DOI:10.4103/sajc.sajc_276_16  PMID:29404289
Aim: Data regarding the optimal management of metastatic anorectal melanoma (mARM) is scarce. The primary aim was to evaluate the potential benefits of systemic therapy in mARM. Materials and Methods: This is a retrospective analysis of all mARM who presented between July 2013 and June 2015 at the Department of GI Medical Oncology, Tata Memorial Hospital. Results: Of a total of 37 patients, twelve patients were planned for best supportive care (BSC) only while the remaining 25 patients received systemic therapy. The median overall survival (OS) for the whole cohort was 27 weeks. The OS was significantly better in patients who received first-line therapy as compared to those who were offered BSC (median OS: 14 vs. 33 weeks; P = 0.04). Patients with PS of 1 did significantly better than PS of 2 more (OS 70 vs. 17 weeks; P = 0.015). Conclusion: mARM should be offered chemotherapy, especially in good performance patients. Paclitaxel/Platinum or Capecitabine/Temozolomide regimens can be considered as the preferred regime in the resource-limited setting where immunotherapy may not be a feasible option.
  1,230 121 -
Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
Vikas Ostwal, Tarachand Gupta, Supriya Chopra, Sherly Lewis, Mahesh Goel, Shraddha Patkar, Nitin Shetty, Anant Ramaswamy
October-December 2017, 6(4):144-146
DOI:10.4103/sajc.sajc_44_17  PMID:29404288
Background: The current standard of treatment for advanced hepatocellular cancer Hepatocellular carcinoma (HCC) is Sorafenib. Data regarding its tolerance and adverse event profile in Indian patients is scarce. Materials and Methods: The primary aim of this analysis was to assess the adverse events (Grade 3 and Grade 4 as per CTCAE v4.0) and requirements for dose reduction with sorafenib in advanced HCC. Details of consecutive patients started on 800 mg/day dosing were obtained from a prospectively maintained database (over a period of 6 months) and analyzed. Results: Thirty-nine patients were available for inclusion in the study. Median age was 58 years (range: 20–75). All patients were classified as Barcelona clinic liver cancer C. Common side effects seen were liver dysfunction (38.5%), hand-foot-syndrome-rash (HFSR) (Grade 2 and 3-25.6%), fatigue (Grade 2 and Grade 3–10.3%), and diarrhea (7.7%). Dose reduction was required in 43.6% of patients. Drug interruptions/cessation was required in 38.5% of patients within the first four months of treatment. Nearly 41% of patients required cessation of sorafenib due to intolerable side-effects while 28.2% stopped sorafenib due to progressive disease. At a median follow-up of 4.9 months, median event-free survival (EFS) was 4.20 months (95% confidence interval: 3.343–5.068). Conclusion: A higher incidence of liver dysfunction and HFSR is seen in Indian patients as compared to published data. A significant proportion of patients required cessation of sorafenib due to adverse events in our series. However, EFS remains on par with that seen in larger studies with sorafenib in advanced HCC.
  1,117 167 -
ORIGINAL ARTICLES: LUNG CANCER
Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India
Randeep Singh, Nitesh Rohtagi
October-December 2017, 6(4):171-175
DOI:10.4103/sajc.sajc_63_17  PMID:29404298
Aims: The primary objective of this study was to estimate the clinicopathological and molecular profile of lung cancer patients along with the evaluation of their clinical characteristics at a tertiary care hospital in Northern India. Subjects and Methods: A total of 421 patients with lung cancer histology who were treated at Max Super Speciality Hospitals were included in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and permission was obtained from the Ethics Committee before the start of the study. Clinical characteristics and molecular profiling data were collected from the patient's medical records. Results: There were 330 (78.4%) men and 91 (21.6%) women with a median age of 62 years (range: 30–93 years). Of the 421 patients, 388 (92.2%) patients had the nonsmall cell lung cancer (NSCLC) histology whereas 33 (7.8%) patients were of SCLC histology. Histology and gender had a significant association with NSCLC and SCLC (P < 0.05). Epidermal growth factor receptor (EGFR) and echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene testing was done in 120 and 93 patients, respectively. Of the 120 patients, 24 (20%) cases were positive for EGFR mutations whereas EML4-ALK fusion gene was present in 8 (8.6%) out of 93 patients. Conclusions: Our study confirms the importance of molecular testing in the NSCLC patient subgroup with an aim to identify the exact molecular targets that can benefit from the newer generation of targeted therapies.
  1,089 130 1
ORIGINAL ARTICLE: LEUKEMIA & LYMPHOMA
Primary central nervous system lymphoma in immunocompetent patients: A regional cancer center experience
AH Rudresha, Tamojit Chaudhuri, Kuntegowdanahalli C Lakshmaiah, Govind Babu, KN Lokesh, LK Rajeev
October-December 2017, 6(4):165-168
DOI:10.4103/2278-330X.221341  PMID:29404295
Background: Primary central nervous system lymphoma (PCNSL) is a rare form of aggressive extranodal non-Hodgkin's lymphoma which occurs in both immunocompromised and immunocompetent patients. It has an overall poor prognosis in spite of a multimodality treatment approach including chemotherapy and radiotherapy. This study attempts to further delineate the clinicopathological, immunohistochemical, and radiological profile of PCNSL at Kidwai Memorial Institute of Oncology, Karnataka, India. Materials and Methods: All the pathologically confirmed PCNSL cases between January 2010 and June 2016, at our center, were analyzed retrospectively. The influence of potential prognostic parameters on overall survival (OS) was investigated by log-rank test and Cox regression analysis. Results: Of the 26 PCNSL patients, 17 (65.3%) were males. Median age at diagnosis was 42.5 years. None of the patients had HIV or Epstein-Barr virus positivity and only four patients (15.4%) had B-symptoms. The most common location in the brain was cerebral hemispheres in 15 patients (57%) and 10 patients (38.5%) had multiple intracranial lesions. Histologically, all were diffuse large B-cell lymphomas, except one case of anaplastic large cell lymphoma. Immunohistochemically, 18 patients (69%) had MUM 1 positivity and 20 cases (77%) belonged to nongerminal center subtype. DeAngelis protocol was followed in 24 patients (92%), and among this cohort, Memorial Sloan Kettering Cancer Center Class 1 (n = 17) and Class 2 (n = 7) patients had a median OS of 25 months and 11 months, respectively. Conclusion: None of the potential prognostic factors had a statistically significant influence on OS in our patients. High-dose methotrexate combined with radiation is an effective therapeutic approach. However, further prospective studies with a large number of patients are needed to identify more effective primary chemotherapy regimens to further improve the treatment outcome.
  1,097 111 2
ORIGINAL ARTICLES: PEDIATRIC AND ADOLESCENT CANCERS
Adolescents and young adults: A study of distribution of cancer at ages 15–39 years in a tertiary care hospital from North India: Epidemiological considerations
Neha Kakkar, Ajay Gupta, Neeraj Kumar Sharma, Prachi Agarwal, Jaspreet Kaur
October-December 2017, 6(4):180-182
DOI:10.4103/sajc.sajc_263_16  PMID:29404301
Purpose: This study aimed to analyze cancer pattern among adolescents and young adults (AYA) in a tertiary care center in North India. Materials and Methods: A retrospective study from January 2011 to December 2014 was undertaken on AYA cancer patients (aged 15–39 years). Results: Totally 1077 cases of AYA cancers were identified for analyzing the frequency and pattern of cancer distribution. The most common cancer was head and neck (32%) followed by breast (14.2%). The distribution pattern was observed to be varying in different age groups with lymphoma, leukemia, bone tumors, and sarcomas in adolescents while carcinomas being more frequent in young adults. Conclusion: Cancer distribution patterns are distinct among AYA in terms of epidemiology and biology.
  1,072 104 -
ORIGINAL ARTICLE: HEAD AND NECK CANCER
Short message service prompted mouth self-examination in oral cancer patients as an alternative to frequent hospital-based surveillance
Sagar Vaishampayan, Akshat Malik, Prashant Pawar, Kavi Arya, Pankaj Chaturvedi
October-December 2017, 6(4):161-164
DOI:10.4103/sajc.sajc_258_16  PMID:29404294
Introduction: Oral squamous cell carcinoma (OSCC) are amongst commonest cancer in the Indian sub-continent. After treatment, these patients require frequent followup to look for recurrences/second primary. Mouth Self Examination (MSE) has a great potential in all levels of prevention of oral cancer. However, the compliance to self-examination has been reported as poor. Mobile phone is a cheap and effective way to reach out to people. Short Message Service (SMS) is extremely popular can be a very effective motivational and interactive tool in health care setting. Methodology: We aimed to identify in adequately treated OSCC patients, the influence of health provider initiated SMS on the compliance to the MSE and to establish the efficacy of MSE by comparing patients' MSE interpretation via replies to the SMS with that of the experts' opinion on clinical examination status during follow up. Conclusion: We conclude that MSE can be very useful in adequately treated OSCC patients for evaluating disease status. All treated OSCC patients must be adequately educated for MSE as an integral part of treatment & follow-up protocol by the health provider facility. Health provider generated SMS reminders do improve motivation and compliance towards MSE but don't seem to reduce dropouts in follow up for large and diverse population like that in India.
  1,027 97 -
LETTERS TO THE EDITOR
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Vanita Noronha, Swaratika Majumdar, Amit Joshi, Vijay Patil, Vaishakhi Trivedi, Anuradha Chougule, Kumar Prabhash
October-December 2017, 6(4):143-146
DOI:10.4103/sajc.sajc_202_17  PMID:29404287
  952 167 1
ORIGINAL ARTICLE: GENITOURINARY & GYNECOLOGICAL CANCERS
Prognostic significance of bone only metastasis compared to visceral metastasis in patients with carcinoma cervix treated with platinum-based chemotherapy
Suresh Babu Mallekavu, Aditi Harsh Thanky, Govind Babu Kanakasetty, Lakshmaiah Kuntegowdanahalli, Lokanatha Dasappa, Linu A Jacob
October-December 2017, 6(4):151-153
DOI:10.4103/sajc.sajc_183_16  PMID:29404291
Context: Carcinoma cervix is a leading cause of cancer in Indian females where 15%–60% of the cases eventually metastasize. Bone only metastasis is rare, and data on its response and survival with systemic therapy as compared to other visceral metastasis are limited. Settings and Design: The study design was a retrospective analysis. Materials and Methods: We retrospectively analyzed our data between May 2013 and April 2015 to identify the cases of bone only metastasis and visceral metastasis and tried to analyze their outcomes with paclitaxel- and carboplatin-based chemotherapy and bisphosphonates (for bone metastasis only). Results: Totally, 12 cases with bone only metastasis (Group 1) and 43 cases with visceral metastasis (Group 2) were identified. Most common sites of bone metastasis were vertebrae (66.67%) and pelvis (25%) while that of visceral metastasis was liver (44.18%) and lung (34.88%). Only 33.33% and 34.88% of cases in Group 1 and Group 2, respectively, could complete all six cycles of chemotherapy. Overall, response rates were 41.67% and 30.32% in Group 1 and Group 2, respectively. Median progression-free survival and overall survival (OS) were 10 months and 14 months, respectively, in Group 1 as compared to 4 months and 9 months, respectively, in Group 2. The difference in survival was statistically significant. Statistical Analysis Used: It was carried out by SPSS software version 20. Conclusion: Bone only metastasis is a rare and distinct entity with favorable outcomes as compared to visceral metastasis. However, disease remains aggressive and poor OS emphasizing the need of further research.
  1,017 83 -
ORIGINAL ARTICLE: SUPPORTIVE CARE
Profile of patients undergoing palliative radiotherapy: A single-institute study from a tertiary care oncology center
Virender Suhag, BS Sunita, Pankaj Vats, Nilotpal Chakravarty, Mayuri Jain, Rekha S Vashisht
October-December 2017, 6(4):190-193
DOI:10.4103/sajc.sajc_149_17  PMID:29404305
Background: Palliative radiotherapy (PRT) plays a significant role in the palliation of symptoms in patients with cancer and constitutes nearly 50% of the workload in different settings. Aims: The aim is to study patient-, disease-, and treatment-related characteristics in locoregionally advanced and metastatic malignancies meriting palliative management. Setting and Design: This was a retrospective observational study in a tertiary care government institute with academic and research potential. Methodology: The electronic medical records, medical documents, and radiotherapy (RT) treatment charts were retrieved and studied. Observations: A total of 460 patients were included in the study over 2 years, forming 30% of the total number of patients treated during the study period. Three hundred and ninety-six patients received PRT to the metastatic sites, while 64 patients received extremely hypofractionated PRT to the primary for symptomatic relief. Totally 442 patients showed good symptomatic response to PRT. One hundred and thirty-eight patients underwent re-irradiation. Lung was the most common primary site seen in 155 cases. The most common indication for PRT was palliation of pain from painful metastases as seen in 240 cases, and the next common indication was palliative whole-brain RT for brain metastases as seen in 159 cases. Conclusion: PRT forms an integral and important aspect of palliative care to the vast number of patients harboring metastatic disease that warrants some form of treatment for symptomatic relief. Short course of PRT in outdoor setting is a preferred mode of treatment to improve the quality of life of these distressed patients.
  970 90 -
ORIGINAL ARTICLES: PEDIATRIC AND ADOLESCENT CANCERS
Epidemiology of cancer in young in central India: An analysis of rural cancer hospital data
Novak Gupta, Prakash Chitalkar, Renu Mishra, Ankur Punia
October-December 2017, 6(4):183-185
DOI:10.4103/sajc.sajc_132_17  PMID:29404302
Background: Cancers in teenage and young adults (TYAs), though an increasing cause of mortality in our country, have been scarcely studied. The lack of studies of TYAs can significantly affect the outcomes of the youth in the prime of their lives. Aims: The aim of this study was to study the type of cancers in the TYA at a rural cancer center in central India. Design and Methods: A prospective study in the department of medical oncology, from the period of January 2013 till March 2016, was done. Data regarding socioepidemiological factors were collected for new cancer patients between the age group of 15–30 years in semi-structured questionnaire and from the hospital records. Cancers were classified according to the Birch classification. The cases were analyzed according to the epidemiological profile, classification of cancer, and age-wise distribution using descriptive analysis. Results: In this study, out of 5221 cancer patients, TYAs accounted for 327 (6.26%) with 189 males and 138 females (M: F– 1.37:1). The maximum cases were seen in 25–30 years' age group. Carcinoma was the most common malignancy (54.74%) with an increase from 19.56% in the 15–19 years' age group to 64.82% in the 25–30-year-old patients. Conclusion: The present study gives a glimpse of the TYA cancers in the central India. More than half of the young cancer patients suffer from carcinomas with about half of these being head and neck cancers.
  933 68 1
NOTICE OF RETRACTION
Retraction: Recurrent Glioblastoma: Where we stand

October-December 2017, 6(4):153-153
DOI:10.4103/2278-330X.221358  PMID:29404292
  904 88 -
LETTERS TO THE EDITOR
Myoepithelial carcinoma of the breast: Case report of a rare entity and its response to chemotherapy
Sanyo P Dsouza, Ajit Kulkarni, Nandini Sharma, SD Banavali
October-December 2017, 6(4):185-194
DOI:10.4103/sajc.sajc_75_17  PMID:29404303
  859 116 3
ORIGINAL ARTICLE: SUPPORTIVE CARE
EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden
Amit Joshi, Vijay M Patil, Vanita Noronha, Anant Ramaswamy, Sudeep Gupta, Atanu Bhattacharjee, Avinash Bonda, MV Chandrakanth, Vikas Ostwal, Navin Khattry, Shripad Banavali, Kumar Prabhash
October-December 2017, 6(4):186-189
DOI:10.4103/sajc.sajc_128_17  PMID:29404304
Background: We are a tertiary care cancer center and have approximately 1000–1500 emergency visits by cancer patients undergoing treatment under the adult medical oncology unit each month. However, due to the lack of a systematic audit, we are unable to plan steps toward the improvement in quality of emergency services, and hence the audit was planned. Methods: All emergency visits under the adult medical oncology department in the month of July 2015 were audited. The cause of visit, the demographic details, cancer details, and chemotherapy status were obtained from the electronic medical records. The emergency visits were classified as avoidable or unavoidable. Descriptive statistics were performed. Reasons for avoidable emergency visits were sought. Results: Out of 1199 visits, 1168 visits were classifiable. Six hundred and ninety-six visits were classified as unavoidable (59.6%, 95% CI: 56.7–62.4), 386 visits were classified as probably avoidable visit (33.0%, 95% CI: 30.4–35.8) whereas the remaining 86 (7.4%, 95% CI: 6.0–9.01) were classified as absolutely avoidable. Two hundred and ninety-seven visits happened on weekends (25.6%) and 138 visits converted into an inpatient admission (11.9%). The factors associated with avoidable visits were curative intention of treatment (odds ratio - 2.49), discontinued chemotherapy status (risk ratio [RR] - 8.28), and private category file status (RR – 1.89). Conclusion: A proportion of visits to emergency services can be curtailed. Approximately one-fourth of patients are seen on weekends, and only about one-tenth of patients get admitted.
  880 82 -
ORIGINAL ARTICLES: LUNG CANCER
Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as the diagnostic modality in a significant subset
Koushik Chatterjee, Raja Bhowmik, Bhargab Chattopadhyay
October-December 2017, 6(4):169-170
DOI:10.4103/sajc.sajc_65_17  PMID:29404296
Context: Regional epidemiology of anaplastic lymphoma kinase (ALK) mutation in non-small-cell lung cancer (NSCLC) is an unmet need in India, and so is the knowledge of its incidence based on immunohistochemistry (IHC). Aims: Reporting the incidence of ALK mutation in NSCLC from Kolkata, incorporating IHC as the diagnostic modality in a considerable subset of patients. Subjects and Methods: It is a retrospective observational study done on NSCLC patients with adenocarcinoma histology, unselected by epidermal growth factor receptor, whose samples were tested for ALK mutation status between March 1, 2013, and March 15, 2017. The study involved all cancer facilities in Kolkata, except Tata Medical Centre. Up to June 2015, the tests were done by fluorescence in situ hybridization (FISH) and from July 2015 to the end, tests were done using IHC, as per the standard testing guidelines existing during the respective time periods. Results were documented in a de-identified manner to analyze the incidence of ALK mutations. Results: A total of 379 patients was tested for ALK mutations. March 2013 to June 2015, 200 (52.77%) patients were tested by FISH, 17 (8.5%) samples were unreportable and 4 patients [(2.19%) 4/183] tested positive for ALK mutations. From July 2015 to March 2017, 179 (47.22%) patients were tested by IHC, 9 (5.02%) samples were unreportable, and 10 patients [(5.88%) 10/170] tested positive for ALK mutations. Overall, 26 (6.8%) samples were unreportable and 14 [(3.9%) 14/353] patients tested positive for ALK mutations. Conclusions: The overall incidence of ALK mutation positive NSCLC in Kolkata is 3.9%. The incidence by IHC is 5.88% and by FISH is 2.19%, in the subset of patients tested by these two modalities respectively.
  878 84 1
LETTERS TO THE EDITOR
Good response to erlotinib in a patient after progression on osimertinib: A rare case of spatiotemporal T790M heterogeneity in a patient with epidermal growth factor receptor-mutant nonsmall cell lung cancer
Venkata Pradeep Babu Koyyala, Ullas Batra, Parveen Jain, Mansi Sharma, Pankaj Goyal, Kshitiz Domadia, Sneha Botra
October-December 2017, 6(4):179-185
DOI:10.4103/sajc.sajc_209_17  PMID:29404300
  811 126 1
Musculoskeletal chronic graft versus host disease – A rare complication of allogeneic hematopoietic stem cell transplantation: A case report and review of its literature
Vasu Babu Goli, Reetu Jain, Ganapathi Bhat, Anjana Sainani, SH Advani
October-December 2017, 6(4):150-168
DOI:10.4103/sajc.sajc_145_17  PMID:29404290
  755 87 -
Triple primary malignancies in head-and-neck region: A report of four cases
Manjari Shah, Rashi Agarwal, Sweety Gupta, Shashank Srinivasan, Prekshi Chaudhary, Sandeep Agarwal, Sudarsan De
October-December 2017, 6(4):194-195
DOI:10.4103/sajc.sajc_225_17  PMID:29404306
  701 84 -
Cutaneous Hodgkin's lymphoma
Asawari Anant Ambekar, Chitralekha S Soman
October-December 2017, 6(4):170-175
DOI:10.4103/sajc.sajc_195_17  PMID:29404297
  696 65 -
Feedback
Subscribe